Claudia A M Fulgenzi - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

Claudia A M Fulgenzi

Showing results (1-10 of 32) with videos related to

Pageof 4

Sort By:

Gut|April 29, 2025

Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunctionMatthias Pinter, Claudia A M Fulgenzi, David J Pinato, et al.

Current Treatment Options in Oncology|August 23, 2021

Immunotherapy in Hepatocellular CarcinomaClaudia A M Fulgenzi, Thomas Talbot, Sam M Murray, et al.

European Journal of Cancer (Oxford, England : 1990)|August 15, 2022

Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trialsClaudia A M Fulgenzi, Antonio D'Alessio, Chiara Airoldi, et al.

JGH Open : an Open Access Journal of Gastroenterology and Hepatology|June 10, 2020

Outcome of acute pancreatitis in octogenarians: A retrospective studyDavide Di Mauro, Chinthaka N Wijesurendere, Andrea Attanasio, et al.

Gut|December 10, 2024

Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse eventsEleonora De Martin, Claudia A M Fulgenzi, Ciro Celsa, et al.

Cancer|June 21, 2022

Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trialAlessio Cortellini, Biagio Ricciuti, Hossein Borghaei, et al.

BMC Cancer|July 2, 2025

STARKAP Protocol: preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi's SarcomaClaudia A M Fulgenzi, Alessia Dalla Pria, Alberto Giovanni Leone, et al.

Future Oncology (London, England)|April 25, 2023

PETAL protocol: a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinomaPetros Fessas, Bernhard Scheiner, Antonio D'Alessio, et al.

JAMA Oncology|August 14, 2025

Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-AnalysisCiro Celsa, Gabriele Di Maria, Pasquale Lombardi, et al.

JHEP Reports : Innovation in Hepatology|May 17, 2023

Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinomaDavid J Pinato, Xiaoxue Li, Pallavi Mishra-Kalyani, et al.

Pageof 4

Search research articles

Showing results (1-10 of 32) with videos related to

Sort By:

Pageof 4

Gut|April 29, 2025

Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunctionMatthias Pinter, Claudia A M Fulgenzi, David J Pinato, et al.

Current Treatment Options in Oncology|August 23, 2021

Immunotherapy in Hepatocellular CarcinomaClaudia A M Fulgenzi, Thomas Talbot, Sam M Murray, et al.

European Journal of Cancer (Oxford, England : 1990)|August 15, 2022

Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trialsClaudia A M Fulgenzi, Antonio D'Alessio, Chiara Airoldi, et al.

JGH Open : an Open Access Journal of Gastroenterology and Hepatology|June 10, 2020

Outcome of acute pancreatitis in octogenarians: A retrospective studyDavide Di Mauro, Chinthaka N Wijesurendere, Andrea Attanasio, et al.

Gut|December 10, 2024

Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse eventsEleonora De Martin, Claudia A M Fulgenzi, Ciro Celsa, et al.

Cancer|June 21, 2022

Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trialAlessio Cortellini, Biagio Ricciuti, Hossein Borghaei, et al.

BMC Cancer|July 2, 2025

STARKAP Protocol: preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi's SarcomaClaudia A M Fulgenzi, Alessia Dalla Pria, Alberto Giovanni Leone, et al.

Future Oncology (London, England)|April 25, 2023

PETAL protocol: a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinomaPetros Fessas, Bernhard Scheiner, Antonio D'Alessio, et al.

JAMA Oncology|August 14, 2025

Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-AnalysisCiro Celsa, Gabriele Di Maria, Pasquale Lombardi, et al.

JHEP Reports : Innovation in Hepatology|May 17, 2023

Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinomaDavid J Pinato, Xiaoxue Li, Pallavi Mishra-Kalyani, et al.

Pageof 4